PHARMAIDS PHARMACEUTICALS LTD.

Pharmaids Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from July 01, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting to consider these financial results will be communicated later. The company will also update its website with this information.

Pharmaids Pharmaceuticals Ltd has announced the resignation of Dr. Jagadeesh M N from his position as Vice President – Discovery Services, a key Senior Management Personnel. The resignation is effective from the closure of business hours on June 25, 2026, and is stated to be for personal reasons. The company has provided the necessary disclosures as per SEBI regulations and made the information available on its website. This change in senior management personnel is a significant event for the company's operational continuity and strategic direction in its discovery services division.

Pharmaids Pharmaceuticals Ltd has issued a corporate guarantee of ₹55,00,000 to State Bank of India on behalf of its unlisted material subsidiary, Adita Bio Sys Private Limited. This guarantee secures a new loan facility for Adita under the Emergency Credit Line Guarantee Scheme (ECLGS) 5.0. The company stated that the promoter/promoter group/group companies have no interest in this transaction, and it is conducted at arm's length. The guarantee represents a contingent liability for Pharmaids Pharmaceuticals Ltd, with no immediate impact on the company's financials as it pertains to a consolidated group entity.

Pharmaids Pharmaceuticals Ltd's Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, in a meeting held on May 29, 2026. They also approved a corporate guarantee not exceeding ₹75,00,000 for Adita Bio Sys Private Limited, a material subsidiary, under the Emergency Credit Line Guarantee Scheme (ECLGS) 5.0. The board meeting commenced at 05:02 P.M. and concluded at 05:55 P.M.

Pharmaids Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial results (standalone & consolidated) for the quarter and financial year ended March 31, 2026. The trading window for dealing in the company's securities will remain closed for designated persons and their immediate relatives until 48 hours after the declaration of the audited financial results.

Pharmaids Pharmaceuticals Ltd has announced the closure of the trading window for designated persons and their immediate relatives. This decision is in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct and Policies for Prevention of Insider Trading. The trading window will remain closed from April 01, 2026, till 48 hours after the declaration of Audited Financial Results of the Company for the Quarter and Year ended March 31, 2026. The date of the Board Meeting for consideration of the Audited Financial Results will be intimated in due course.

Pharmaids Pharmaceuticals Ltd. has announced that its material subsidiary, Adita Bio Sys Private Limited, has received accreditation by the American Association for Laboratory Accreditation (A2LA) for testing of medical devices in the biological field. The accreditation is as per International Standard ISO/IEC 17025:2017 and U.S. FDA Good Laboratory Practice (GLP) Regulations per 21 CFR Part 58. This significant development enhances the company's competence in testing and calibration laboratories, and reinforces its commitment to quality and compliance in the pharmaceutical sector.

Pharmaids Pharmaceuticals Ltd has released its unaudited quarterly standalone financial results for the quarter and nine months ended December 31, 2025. The results were reviewed by PPKG & Co Batgach, the independent auditor, in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The review was conducted to obtain moderate assurance as to whether the financial statements are free of material misstatement. The Statement is prepared in accordance with the Ind AS 34, prescribed under Section 133 of the Companies Act, 2013. The review report does not express an audit opinion but concludes that nothing has come to their attention that causes them to believe that the Statement is not free of material misstatement. The Statement includes the results of Adita Bio Sys Private Limited, Sirl Labvivo Diet Private Limited, and Spring Labs, all step-down subsidiaries of the company.

Pharmaids Pharmaceuticals Ltd, a prominent player in the pharmaceutical industry, has announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company's revenue from operations stands at 83.28 Lacs for the quarter and 596.55 Lacs for the nine months ended period. The total income for the quarter is 89.37 Lacs and 615.61 Lacs for the nine months ended period. The company's expenses for the quarter are 13.12 Lacs and 1,162.05 Lacs for the nine months ended period. The profit before tax for the quarter is negative (423.75) Lacs and negative (233.38) Lacs for the nine months ended period. The total tax expense for the quarter is negative (112.77) Lacs and negative (68.15) Lacs for the nine months ended period. The profit for the year is negative (310.98) Lacs and negative (165.23) Lacs for the nine months ended period. The earnings per equity share (basic and diluted) for the year are Rs. (0.88) and Rs. (0.47) respectively.

Pharmaids Pharmaceuticals Ltd, a leading pharmaceutical company, announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's revenue from operations stands at 83.28 Lacs for the quarter and 596.55 Lacs for the nine months period. The total income for the quarter is 89.37 Lacs and 615.61 Lacs for the nine months. The company's profit before tax for the quarter is -423.75 Lacs and -233.38 Lacs for the nine months. The total comprehensive income for the year is -727.22 Lacs. The company's earnings per equity share (basic and diluted) for the year is Rs. 2.06.